Singapore: Australia-based bioCSL has joined forces with New Zealand-based ALK to commercialize three ALK allergy immunotherapy products in Australia and New Zealand. As per the agreement, ALK will be responsible for product supply and bioCSL will undertake commercialization and registration of the products.

Allergic rhinitis is one of the most common respiratory illnesses in Australia, affecting nearly 18 percent of the country's population. Allergic rhinitis coexists with other allergic conditions like asthma and sinusitis.

Dr John Anderson, GM, bioCSL, said, "We recognize that access to more therapy options is very important to Australian healthcare professionals and allergy sufferers. We are happy to collaborate with ALK for the distribution, marketing and sales of these products which are important additions to bioCSL's growing product range and further strengthens our broad portfolio of in-licensed medicines in Australia."

Mr Jens Bager, president and CEO, ALK said, "The partnership will help in expanding the reach of ALK's products by entering new growth markets. bioCSL is a large pharmaceutical company in Australia and with a prominent track record in vaccines and adrenaline auto-injectors."